The FDA’s recent decision to remove Eli Lilly’s diabetes and weight-loss drug tirzepatide from its drug shortage list has sparked a legal battle, creating uncertainty for compounding pharmacies. The Outsourcing Facilities Association (OFA) and North American Custom Laboratories, LLC, doing business as Farmakeio Custom Compounding, have filed a lawsuit in Texas federal court challenging the FDA’s decision. Both plaintiffs are large 503B outsourcing facilities, with OFA serving as the trade association for 503Bs, and Farmakeio being a prominent 503B facility. This case is likely to have significant implications for outsourcing facilities and compounding pharmacies alike, especially those relying on tirzepatide’s previous shortage designation to justify compounding.
Tirzepatide, the key ingredient in Eli Lilly’s Mounjaro, had been listed on the FDA’s drug shortage list, allowing 503B facilities to produce versions of the drug to meet patient demand. These compounded formulations became a valuable alternative for patients seeking affordable options for diabetes and weight loss treatments. However, with the FDA’s decision to remove tirzepatide from the shortage list, pharmacies now face increased regulatory scrutiny and the potential for legal action, particularly from manufacturers like Eli Lilly.
In response to this shift, OFA and Farmakeio Custom Compounding launched their lawsuit aimed at overturning the FDA’s decision, arguing that the removal of tirzepatide from the shortage list is flawed and detrimental to both patient care and access to affordable medications. The outcome of this lawsuit will be crucial for 503B outsourcing facilities and other compounding pharmacies, determining whether they can continue compounding tirzepatide without facing legal repercussions.
The FDA’s actions present immediate challenges for 503B outsourcing facilities and compounding pharmacies. Pharmacies that continue compounding tirzepatide now face heightened regulatory oversight from both federal agencies and state boards of pharmacy. Pharmacies must ensure they are fully compliant with USP standards and state-specific regulations, as audits and inspections are likely to increase. Pharmacies also risk receiving cease-and-desist letters or lawsuits from manufacturers like Eli Lilly, adding another layer of legal exposure.
With tirzepatide being a popular treatment option for diabetes and weight loss, 503B outsourcing facilities and compounding pharmacies will need to carefully navigate these new legal and regulatory risks. Patient care could be impacted as pharmacies explore alternative solutions to meet demand, all while staying within the bounds of current regulations.
In this environment, it’s essential for 503B outsourcing facilities and compounding pharmacies to be proactive. Monitoring the legal developments surrounding the tirzepatide lawsuit and staying informed about regulatory changes will be crucial. Pharmacies should also consider consulting with legal counsel experienced in compounding pharmacy law to mitigate the risks posed by these regulatory and legal shifts. Strengthening compliance practices by ensuring adherence to relevant USP standards, as well as conducting regular internal audits, can help prepare pharmacies for potential inspections and enforcement actions as well.
While the future remains unclear, the current situation highlights the growing challenges that 503B outsourcing facilities and compounding pharmacies face in today’s regulatory landscape. Taking action now will ensure their long-term viability and protect their ability to meet patient needs.
How Frier Levitt Can Help
In light of this FDA update, there may be some difficulty in navigating FDA and state rules/regulations for compounding when a drug is removed from the FDA shortage list. Frier Levitt has experience in representing both 503A compounding pharmacies and 503B outsourcing facilities in these matters. We regularly counsel clients on Section 503A and state-specific compounding requirements, assess compounding practices for state and federal regulatory compliance, including USP 797/795/800, medical necessity documentation, advertising, promotion, reimbursement issues, infrastructure, and preparing compounding policies and procedures that provide clear guidelines, standards and training for staff. Contact us to discuss your specific needs.
Related Article:
Check out “FDA Still Undecided if Tirzepatide is in Shortage” for the latest update.
